Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.97
+1.0%
$4.68
$2.92
▼
$6.45
$318.79M0.76380,659 shs416,459 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$13.09
-2.7%
$10.75
$5.65
▼
$13.85
$460.93M1.29210,266 shs397,643 shs
Immunic, Inc. stock logo
IMUX
Immunic
$6.99
-5.4%
$8.29
$5.06
▼
$17.43
$111.00M1.48296,035 shs295,662 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$2.62
-15.8%
$3.68
$2.60
▼
$8.00
$279.53M0.621.51 million shs2.24 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-1.50%-6.65%-12.08%-27.62%+24.76%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+0.90%+23.39%+28.59%+19.13%+64.43%
Immunic, Inc. stock logo
IMUX
Immunic
-1.60%-5.01%-0.13%-55.15%+4.23%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
+8.74%-25.24%-7.44%-32.83%-25.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.97
+1.0%
$4.68
$2.92
▼
$6.45
$318.79M0.76380,659 shs416,459 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$13.09
-2.7%
$10.75
$5.65
▼
$13.85
$460.93M1.29210,266 shs397,643 shs
Immunic, Inc. stock logo
IMUX
Immunic
$6.99
-5.4%
$8.29
$5.06
▼
$17.43
$111.00M1.48296,035 shs295,662 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$2.62
-15.8%
$3.68
$2.60
▼
$8.00
$279.53M0.621.51 million shs2.24 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-1.50%-6.65%-12.08%-27.62%+24.76%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+0.90%+23.39%+28.59%+19.13%+64.43%
Immunic, Inc. stock logo
IMUX
Immunic
-1.60%-5.01%-0.13%-55.15%+4.23%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
+8.74%-25.24%-7.44%-32.83%-25.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$8.00101.51% Upside
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
3.00
Buy$17.5033.70% Upside
Immunic, Inc. stock logo
IMUX
Immunic
2.85
Moderate Buy$32.71368.02% Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.75
Moderate Buy$12.00358.02% Upside

Current Analyst Ratings Breakdown

Latest IMUX, FENC, AVIR, and RLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Immunic, Inc. stock logo
IMUX
Immunic
Reiterated RatingBuy$3.00
11/18/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Boost Price TargetBuy$16.00 ➝ $17.00
11/16/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Boost Price TargetEqual Weight$7.00 ➝ $8.00
11/16/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Reiterated RatingBuy$18.00 ➝ $19.00
11/13/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
UpgradeSell (D-) ➝ Hold (C-)
11/12/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
UpgradeHold ➝ Strong-Buy
11/10/2026
Immunic, Inc. stock logo
IMUX
Immunic
DowngradeStrong-Buy ➝ Hold
10/23/2026
Immunic, Inc. stock logo
IMUX
Immunic
Initiated CoverageOverweight
10/21/2026
Immunic, Inc. stock logo
IMUX
Immunic
UpgradeHold ➝ Strong-Buy
10/15/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Reiterated RatingSell (D-)
10/15/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Reiterated RatingSell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$2.19 per shareN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$66.37M6.95N/AN/A$1.40 per share9.35
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$6.58 per shareN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.82 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$1.95N/AN/AN/AN/A-69.91%-61.22%N/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$9.74M$0.011,308.9012.83N/A2.52%8.96%4.90%N/A
Immunic, Inc. stock logo
IMUX
Immunic
-$97.17M-$4.07N/AN/AN/AN/A-136.26%-100.75%N/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$57.38M-$0.72N/AN/AN/AN/A-37.25%-34.87%N/A

Latest IMUX, FENC, AVIR, and RLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Immunic, Inc. stock logo
IMUX
Immunic
-$0.7852-$0.99-$0.2048-$0.99N/AN/A
11/12/2026Q3 2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$0.0960$0.12+$0.0240$0.12$18.87 million$19.61 million
11/12/2026Q3 2026
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.1450-$0.12+$0.0250-$0.12N/AN/A
11/9/2026Q3 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.51-$0.40+$0.11-$0.40$50.45 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.00
8.00
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
6.11
5.95
Immunic, Inc. stock logo
IMUX
Immunic
N/A
4.28
5.05
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
26.37
26.37

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
55.51%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
10.73%
Immunic, Inc. stock logo
IMUX
Immunic
5.49%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
14.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
5580.30 million62.96 millionOptionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
3535.22 million31.44 millionOptionable
Immunic, Inc. stock logo
IMUX
Immunic
9515.88 million15.01 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
17106.69 million91.22 millionOptionable

Recent News About These Companies

HC Wainwright Issues Optimistic Estimate for RLMD Earnings
Relmada Therapeutics appoints Jørn Skibsted Jakobsen as CDO
RLMD Stock Gets Stronger EPS Estimate from HC Wainwright
Relmada (RLMD) Q3 2026 Earnings Call Transcript
Relmada Therapeutics Q3 Loss Narrows
RLMD Share News Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.97 +0.04 (+1.02%)
Closing price 03:58 PM Eastern
Extended Trading
$3.98 +0.00 (+0.13%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$13.09 -0.36 (-2.68%)
Closing price 03:59 PM Eastern
Extended Trading
$13.09 +0.00 (+0.01%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Immunic stock logo

Immunic NASDAQ:IMUX

$6.99 -0.40 (-5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$7.36 +0.38 (+5.36%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$2.62 -0.49 (-15.76%)
Closing price 04:00 PM Eastern
Extended Trading
$2.62 0.00 (-0.19%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.